Curium Bolsters Nuclear Medicine with Monrol Acquisition

Curium Pharma has completed the acquisition of Eczacba-Monrol Nuclear Products Co., a move that positions Curium as a leading manufacturer of the Lu-177 isotope—a critical component in nuclear medicine. The acquisition significantly boosts Curium's manufacturing capacity for Lutetium-177, meeting the growing worldwide demand for this isotope, which is crucial for Curium’s developing drug candidates aimed at prostate cancer and neuroendocrine tumors. Monrol enhances Curium's research and development capabilities and facilitates the global deployment of Monrol’s Ga-68 generator, pending regulatory approvals. With this acquisition, Curium expands its PET (Positron Emission Tomography) and SPECT (Single Photon Emission Computed Tomography) footprints, increasing the number of sites from 34 to 46 by adding Monrol-owned and partnered sites across Eastern Europe and the MENA regions. Additionally, Monrol's infrastructure in Istanbul complements Curium’s vertically integrated production and distribution systems. Curium's CEO of International Markets, Mr. Chaitanya Tatineni, expressed enthusiasm about the enhanced scale and capabilities brought by Monrol, particularly in Lu-177 production, envisaging multiple opportunities to improve diagnostic and therapeutic solutions globally. Management at Monrol and Eczacba Pharmaceutical expressed excitement and pride in joining Curium, highlighting the synergy and expanded potential due to richer technology access and a broadened network.